XORTX extends deadline to complete Vectus acquisition to March
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/5/2026
- Dow claims record closing high, S&P 500 advances; chip selloff weighs on Nasdaq
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- HSBC stays aggressive on stocks, asks what could turn it bearish
- SpaceX sets IPO price at $135 ahead of roadshow in break with Wall Street norms
- Crypto stocks sink as Bitcoin hits a 4-month low
- Wells Fargo Upgrades Oscar Health Inc (OSCR) to Equal Weight 'on Greater Confidence in Exchange Market Trajectory in 2026'
- Broadcom results, guidance beat on soaring AI chip sales; stock slips after hours
- LCI Industries names interim CEO as Jason Lippert retires
- Dow claims record closing high, S&P 500 advances; chip selloff weighs on Nasdaq
- Morgan Stanley lifts MU and SNDK targets, sees 2-3 years of tight memory supply
XORTX Provides Update on Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems
February 4, 2026 6:00 PM ESTCALGARY, Alberta, Feb. 04, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (XORTX or the Company) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that further to its press release of October 17, 2025 and an update on December 31, 2025, the Company has entered into an extension agreement with Vectus Biosystems Limited (Vectus) to allow further time to complete the acquisition of the Renal Anti-Fibrotic Therapeutic Program from Vectus (the Acquisition). The term sheet entered into October 17th (the Term Sheet) to acquire the... More
